CSL Limited, a prominent health care biotechnology company headquartered in Parkville, Australia, continues to be a significant player in the health care sector. The company is renowned for its specialization in the development, manufacturing, and marketing of human pharmaceutical and diagnostic products derived from human plasma. Its diverse product portfolio includes pediatric and adult vaccines, infection and pain medicines, skin disorder remedies, antivenoms, anticoagulants, and immunoglobulins. For more detailed information on their offerings, CSL maintains an online presence at www.csl.com.au .
As of the latest available data, CSL Limited is listed on the ASX All Markets stock exchange, trading under the currency of AUD. The company’s financial metrics as of 19 February 2026, reveal a close price of AUD 153.27. Over the past year, the stock has experienced a 52-week range, with a high of AUD 275.79 recorded on 29 July 2025, and a low of AUD 149.85 on 15 February 2026. This volatility reflects the dynamic nature of the biotechnology sector and market conditions.
CSL’s market capitalization stands at approximately AUD 73.84 billion, underscoring its substantial presence in the industry. The company’s valuation metrics include a price-to-earnings (P/E) ratio of 38.03 and a price-to-book (P/B) ratio of 2.74. These figures suggest that CSL is valued highly in terms of earnings performance and asset backing, indicative of investor confidence in its growth prospects and operational stability.
In terms of corporate developments, CSL Limited has not issued any recent updates. However, the most recent public disclosure, dated 17 February 2026, highlighted a strategic licensing agreement between CSL and Eli Lilly concerning clazakizumab. This collaboration underscores CSL’s ongoing efforts to expand its product pipeline and enhance its market offerings through strategic partnerships.
Overall, CSL Limited remains a key entity in the biotechnology and health care sectors, with a strong focus on innovation and strategic growth initiatives. The company’s robust financial metrics and strategic alliances position it well for continued success in the competitive landscape of health care biotechnology.
